Ovid Therapeutics Inc.
Moat Score — Ovid Therapeutics Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Ovid holds exclusive licenses to real patented mechanisms (the Northwestern-licensed OV329 GABA-aminotransferase inhibitor, the AstraZeneca KCC2 activator library), giving it legally protected IP positions, though none has yet reached commercial approval. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage biotech with no revenue and a finite cash runway into H2 2026, Ovid has no cost advantage; it is a capital consumer, not a low-cost producer, by definition at this stage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved products, Ovid currently sets no prices and exercises no pricing power in the market; any future pricing power is entirely speculative and contingent on regulatory approval. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Drug development and prescribing carry no network effect - a patient's or physician's value from an Ovid therapy would not increase because other patients or physicians also use it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | With no marketed products yet, there are no prescriber or patient switching costs today; any future switching costs would depend on physician familiarity and treatment protocols established after approval, which has not yet happened for any Ovid asset. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Ovid targets rare, underserved neurological indications (CDKL5 deficiency, CCM-related seizures) that are small enough to discourage some large pharma competitors, but several specialized rivals (Marinus, Neurelis, Axonis) are pursuing the same narrow niches. |